Fluarix™
BiologicalSingle intramuscular dose on Day 0
Other names: Influsplit
NCT Number: NCT00706563
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2008-2009 season.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
GSK Investigational Site, Dresden, Saxony, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single intramuscular dose on Day 0
Other names: Influsplit
Time frame: At Day 0 and 21
Titers given as geometric mean titer (GMT) were presented for all three vaccine influenza virus strains
Time frame: At Day 0 and 21
The cut-off value assessed was ≥ 1:10 and was presented for all three vaccine influenza virus strains
Time frame: At Day 0 and 21
A seroprotected subject is a subject with a serum HI antibody titer ≥ 1:40
Time frame: At Day 21
A seroconverted subject is a subject with a pre-vaccination serum HI titer < 1:10 and a post-vaccination serum HI titer ≥ 1:40, or a pre-vaccination serum HI titer ≥ 1:10 and a fold increase (Day 21/Day 0) ≥ 4
Time frame: At Day 21
Seroconversion factor, defined as the fold increase in serum HI GMT post-vaccination compared to pre-vaccination (Day 0), is presented for all three vaccine influenza virus strains
Time frame: At Day 21
Seroprotection power is defined as the number of subject who had a pre-vaccination titer < 1:40 and a post-vaccination titer ≥ 1:40
Time frame: During the 4-day (Day 0-3) post-vaccination period
Solicited local symptoms assessed include ecchymosis, induration, pain, redness, and swelling.
Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, shivering, sweating, and fever
Time frame: During the 21-day (Day 0-20) post-vaccination period
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: During the 21-day (Day 0-20) post-vaccination period
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
GlaxoSmithKline
Industry
A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in People Aged 18 Years or Above
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07737106
Infections, Influenza
Bayan Nur, Inner Mongolia, China
View Trial DetailsNCT06518577
Infections, Influenza
Phoenix, Arizona, United States
View Trial DetailsNCT06560151
Infections, Influenza
Atlanta, Georgia, United States
View Trial Details